We tested drugs and antibodies targeting (1) tumor-expressed receptors, including the RTKs EGFR and AXL, and integrin β1 (heterodimerizing with α-integrins to bind ECM); (2) TAM-expressed receptors influencing TAM polarization, including toll-like receptor 7/8 (TLR7/8) and the RTKs MERTK and CSF1R; (3) PI3K isoforms including leukocyte selective p110δ and p110γ; and (4) Rho-associated protein kinase (ROCK) as a representative effector of Rho-family GTPases. Here, AXL is linked to neoplasm.